BioInvent receives $3m payment for antibodies selected by Pfizer

pharmafile | December 23, 2020 | News story | Research and Development |ย ย BioInvent, Cancer, Pfizerย 

BioInvent International, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, has announced that Pfizer has selected antibodies directed at a previously-selected target under the companies’ cancer immunotherapy research collaboration and licence agreement.

The agreement, into which the companies entered in December 2016, covers developing antibodies from BioInvent’s proprietary F.I.R.S.TTM drug discovery platform targeting tumour-associated myeloid cells.

The selection of these antibodies triggers a payment of $3 million from Pfizer to BioInvent, and BioInvent is eligible for further milestone payments from development of these antibodies and potential selection and development of further antibodies directed at the same target.

Advertisement

Martin Welschof, BioInvent’s CEO, said: โ€œPfizer’s selection of antibodies under our agreement is a great demonstration of the actionable leads generated by our drug discovery technology platform. We are very pleased with how our partnership is progressing and look forward to further strengthening our collaboration.

โ€œOur F.I.R.S.TTM platform is a patient-centric approach, drawing on our high-quality n-CoDeR antibody library to produce promising drug candidates, and we believe this partnership is an important validation of this technology.โ€

Darcy Jimenez

Related Content

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโ€™s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europeโ€™s first XSeed Labs research project, …

T-cell therapy โ€“ the evolution of cancer treatments

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content